Portfolio Companies
Angion Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement
Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications
AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma
Frazier Healthcare and Alpine BioVentures Join in $20M Series A Round for Mavupharma
Alpine Immune Sciences Completes Merger with Nivalis Therapeutics – Now Trading under ALPN on NASDAQ
Nivalis Therapeutics and Alpine Immune Sciences Agree to Combine
Alpine Immune Sciences Announces $48M Series A Financing
Why ex-Dendreon CEO’s New Startup Could Succeed
Former Dendreon CEO Launches Stealth Next-gen Immunotherapy Startup in Seattle
Seattle Biotech Oncothyreon Pays $27 million for Alpine Biosciences
A “Revolution”: Oncothyreon CEO on Alpine Biosciences Acquisition